文献速递神经肿瘤神经重症

TachoSil®作为脑室封闭剂的有效性和安全性:一项观察性队列研究

Effectiveness and safety of Tachosil® as a ventricular sealant: an observational cohort study.
PubMed 文献 · Acta Neurochir (Wien) · 2024-09-27

该单中心前瞻性队列研究纳入2020年12月至2023年11月间39例接受幕上开颅及脑室周围病变择期手术的患者,共40次干预,评估TachoSil®作为脑室封闭剂预防开放脑室系统术后并发症的有效性和安全性。至术后90天,无患者出现药物不良反应,仅2例(5%)出现脑室开放相关手术并发症,均经脑室腹腔分流术解决。作者认为TachoSil®可安全有效地用于脑实质内,但需随机对照临床试验确认。

要点

  • 39例患者共40次干预,中位年龄56岁,60%为高级别胶质瘤。
  • 术后90天内无药物不良反应,仅2例(5%)出现脑脊液动力学相关并发症。
  • 无假性脑膜膨出、感染或封闭剂相关并发症。

核心结论

  • TachoSil®是一种硬脑膜封闭剂,可安全有效地用于涉及脑室开放的脑实质内手术。
  • 仅5%接受治疗的患者出现脑脊液动力学相关并发症。
  • 无患者出现假性脑膜膨出、感染或与封闭剂使用相关的并发症。
  • 作者认为需开展随机对照临床试验评估TachoSil®在开放脑室系统开颅术后患者中的疗效,以确认这些积极结果。

研究设计与样本

  • 单中心前瞻性队列研究,纳入2020年12月至2023年11月间接受幕上开颅及脑室周围病变择期手术的患者。
  • 共39例患者,40次干预,中位年龄56岁。
  • 随访至术后90天,登记脑脊液动力学相关手术并发症、感染、其他并发症、药物不良反应、再干预或再入院。
  • 研究注册于Clinical Trials.gov(NCT05717335),注册日期2022年5月1日。

主要发现

  • 11例患者(28.2%)有同部位既往手术史,5例(12.8%)曾接受放化疗,11例(28.2%)为吸烟者。
  • 24例患者(60%)因高级别胶质瘤手术,8例(20%)因低级别胶质瘤,6例(15%)因转移瘤,2例(5%)因脑膜瘤。
  • 整个研究期间至术后90天,无患者出现药物不良反应。
  • 仅2例患者(5%)出现脑室开放相关手术并发症,其中1例经皮脑脊液漏,1例外性脑积水,均经脑室腹腔分流术解决。
  • 无患者出现假性脑膜膨出、感染或与封闭剂使用相关的并发症。

临床怎么用

  • 作者认为TachoSil®可安全有效地用于涉及脑室开放的脑实质内手术。
  • 作者认为需开展随机对照临床试验评估TachoSil®在开放脑室系统开颅术后患者中的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Surgery close to or in contact with the ventricular system is challenging due to the complications. We sought to evaluate the effectiveness and safety of TachoSil® as a ventricular sealant in preventing complications after cranial surgery with an open ventricular system (OVS). METHODS: This is a single-center and prospective cohort study We included patients who underwent elective surgery for supratentorial craniotomy and periventricular pathology between December 2020 and November 2023. We registered surgical complications arising from CSF dynamics (such as percutaneous cerebrospinal fluid (CSF) leakage, hydrocephalus, pseudomeningocele), infections, and other complications (postsurgical hematoma) adverse drug reactions (ADRs), reintervention or hospital readmission up to 90 days after surgery. RESULTS: Forty interventions were performed on 39 patients, whose median age was 56 years. Eleven patients (28.2%) had antecedents of previous surgery in the same location, 5 (12.8%) had previously received radiotherapy and chemotherapy, and 11 (28.2%) were smokers. Twenty-four patients (60%) underwent surgery for high-grade glioma, 8 (20%) for low-grade gliomas, 6 (15%) for metastasis and 2 (5%) for meningioma. Throughout the study and up to 90 days after surgery, none of the patients presented an ADR. Only 2 patients (5%) presented with a surgery complications derived from ventricular opening (one patient with a percutaneous CSF leakage and one patients with external hydrocephalus). Both patients resolved with a ventriculoperitoneal shunt. CONCLUSIONS: TachoSil® is a dural sealant that can be used safely and effectively intraparenchymally in patients whose surgery involves a ventricular opening. Only 5% of treated patients presented complications arising from CSF hydrodynamics. No patients had pseudomeningocele, infections or complications related to the use of this sealant. To confirm these positive results, randomized and comparative clinical trials assessing the efficacy of TachoSil® in patients after cranial surgery with an OVS are essential. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: This study was registered in the Clinical Trials.gov (NCT05717335). Date May 1st, 2022.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Teixidor-Rodríguez P, Brugada-Bellsolà F, Menéndez-Girón S, et al. Effectiveness and safety of Tachosil® as a ventricular sealant: an observational cohort study. Acta Neurochir (Wien). 2024. PMID: 39331127. doi:10.1007/s00701-024-06276-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。